Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

VIR

Vir Biotechnology Inc

Feb 23 • 04:00PM ET

7.43

-0.13 -1.72 %

Healthcare • Biotechnology • USA • NASD

Feb 23, 7:17 PMVir Biotechnology beats Q4 estimates with non-GAAP EPS -0.31 and revenue $64.1M, announces $335M Astellas collaboration on VIR-5500

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN-D SNY NVAX

| Held by: IJR VTI VB XBI IWM VBK VXF SPSM IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.62	Insider Own	31.94%	Shs Outstand	139.02M	Perf Week	-0.54%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-2.18	Insider Trans	-6.52%	Shs Float	94.68M	Perf Month	0.41%
Enterprise Value	625.14M	PEG	-	EPS next Q	-0.45	Inst Own	56.79%	Short Float	12.92%	Perf Quarter	36.58%
Income	-499.65M	P/S	61.31	EPS this Y	14.06%	Inst Trans	2.70%	Short Ratio	6.04	Perf Half Y	69.63%
Sales	16.86M	P/B	1.30	EPS next Y	19.73%	ROA	-39.69%	Short Interest	12.23M	Perf YTD	23.22%
Book/sh	5.73	P/C	2.03	EPS next 5Y	14.10%	ROE	-49.06%	52W High	9.93 -25.18%	Perf Year	-22.36%
Cash/sh	3.66	P/FCF	-	EPS past 3/5Y	- -18.74%	ROIC	-56.31%	52W Low	4.16 78.82%	Perf 3Y	-71.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.24% 55.77%	Gross Margin	26.74%	Volatility	5.68% 6.37%	Perf 5Y	-88.36%
Dividend TTM	-	EV/Sales	37.08	EPS Y/Y TTM	7.74%	Oper. Margin	-3081.69%	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.25	Sales Y/Y TTM	-78.55%	Profit Margin	-2963.54%	RSI (14)	53.05	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	7.25	EPS Q/Q	24.91%	SMA20	-1.24%	Beta	1.68	Target Price	17.33
Payout	-	Debt/Eq	0.13	Sales Q/Q	-89.92%	SMA50	9.85%	Rel Volume	1.62	Prev Close	7.56
Employees	408	LT Debt/Eq	0.11	Earnings	Feb 23 AMC	SMA200	30.30%	Avg Volume	2.03M	Price	7.43
IPO	Oct 11, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.88% 221.87%	Trades		Volume	12,322,602	Change	-1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Evercore ISI	Outperform	$12
Aug-27-25	Upgrade	BofA Securities	Neutral → Buy	$14
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62

Show Previous Ratings

Today 05:16AM	Stock Market Today: Dow Jones, Nasdaq 100 Futures Gain Amid AI-Led Sell-Off, Trump's Threat To Trading Partners-Whirlpool, Uber, HP In Focus (Benzinga)
12:07AM	Vir Biotechnology Q4 Earnings Call Highlights (MarketBeat)
12:02AM	Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
Feb-23-26 08:55PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:13PM	Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas (Investor's Business Daily)
05:14PM	Loading…
05:14PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
05:02PM	Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer (Business Wire)
05:00PM	Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer (PR Newswire)
Feb-20-26 07:18AM	Vir Biotechnology Inc (VIR) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-09-26 04:05PM	Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-12-26 08:00AM	Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones (Business Wire)
Jan-05-26 04:05PM	Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-25 04:05PM	Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program (Business Wire) -5.25%
Nov-19-25 04:05PM	Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
06:07PM	Loading…
Nov-09-25 06:07PM	Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile (Business Wire)
Nov-07-25 09:00AM	Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference (Business Wire)
Nov-06-25 12:04AM	Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -5.19%
Nov-05-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 08:00AM	Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta (Business Wire) -6.04%
Oct-29-25 11:48AM	GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View (Zacks) -8.09%
Oct-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire) -5.56%
Oct-09-25 04:05PM	Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer (Business Wire)
09:27AM	Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains? (Zacks)
Oct-07-25 08:00AM	Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting 2025 (Business Wire)
Aug-27-25 04:21PM	Vir Stock Soars After BofA Boosts Rating on Liver Therapy (GuruFocus.com) +17.79%
09:34AM	Micron initiated, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-25-25 04:05PM	Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-06-25 06:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -14.37%
04:05PM	Loading…
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results (Business Wire)
08:05AM	Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-31-25 08:05AM	Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Jul-30-25 11:42AM	GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise (Zacks)
10:00AM	Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-25-25 05:50AM	First subject dosed in Phase I trial of Vir Biotechnologys VIR-5525 (Clinical Trials Arena)
Jul-24-25 08:05AM	Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors (Business Wire)
Jul-22-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire)
Jul-14-25 09:52AM	Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board (Business Wire)
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 09:31AM	Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? (Zacks)
May-28-25 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.03%
May-20-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit (Business Wire)
May-12-25 04:05PM	Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference (Business Wire) -11.32%
May-09-25 06:00AM	Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study (Business Wire) -6.01%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 11:21PM	Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus (Seeking Alpha)
11:21PM	Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results (Business Wire)
Apr-30-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
Apr-24-25 09:30AM	Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 (Business Wire) +5.36%
Apr-09-25 09:43AM	Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple (Insider Monkey) +10.21%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 07:10AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results (PR Newswire)
Mar-13-25 08:05AM	Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -11.85%
02:24AM	Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Feb-26-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-12-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire) +5.16%
Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Byrne Jason	Officer	Feb 23 '26	Proposed Sale	7.45	2,089	15,569		Feb 23 04:52 PM
Eisner Mark	Officer	Feb 23 '26	Proposed Sale	7.45	2,089	15,569		Feb 23 04:34 PM
De Backer Marianne	Officer	Feb 23 '26	Proposed Sale	7.45	19,039	141,894		Feb 23 04:32 PM
de Verneuil Vanina	Officer	Feb 23 '26	Proposed Sale	7.45	4,445	33,128		Feb 23 04:22 PM
Sabatini Brent	Officer	Feb 23 '26	Proposed Sale	7.45	1,829	13,631		Feb 23 04:18 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 13 '26	Sale	7.79	1,530	11,919	47,872	Feb 18 03:38 PM
Sabatini Brent	Officer	Feb 13 '26	Proposed Sale	7.79	1,530	11,918		Feb 13 03:46 PM
SATO VICKI L	Director	Feb 02 '26	Sale	7.71	22,000	169,671	1,144,391	Feb 03 12:28 PM
SVF Endurance (Cayman) Limited	Stockholder	Jan 14 '26	Proposed Sale	6.82	1,251,303	8,533,886		Jan 14 09:00 PM
SATO VICKI L	Director	Jan 02 '26	Sale	5.93	22,000	130,383	1,166,391	Jan 05 01:57 PM
VICKI LEE SATO	Director	Jan 02 '26	Proposed Sale	6.03	66,000	397,980		Jan 02 04:29 PM
SVF Endurance (Cayman) Ltd	10% Owner	Dec 01 '25	Sale	5.98	191,854	1,147,786	13,728,924	Dec 03 04:30 PM
SATO VICKI L	Director	Dec 01 '25	Sale	6.00	22,000	132,070	1,188,391	Dec 02 07:48 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 26 '25	Sale	6.39	127,938	817,652	13,982,271	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 28 '25	Sale	6.44	61,493	396,015	13,920,778	Dec 01 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 25 '25	Sale	6.38	235,971	1,505,495	14,110,209	Nov 26 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Nov 24 '25	Sale	6.15	227,803	1,400,783	14,346,180	Nov 26 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Nov 25 '25	Proposed Sale	6.44	1,251,303	8,058,391		Nov 25 09:00 PM
O'Byrne Jason	EVP & Chief Financial Officer	Nov 17 '25	Sale	5.56	6,799	37,782	110,701	Nov 18 02:47 PM
O'Byrne Jason	Officer	Nov 17 '25	Proposed Sale	5.56	6,799	37,781		Nov 17 03:20 PM
de Verneuil Vanina	EVP, General Counsel, Corp Sec	Nov 05 '25	Sale	5.16	2,385	12,307	78,210	Nov 07 03:27 PM
de Verneuil Vanina	Officer	Nov 05 '25	Proposed Sale	5.16	2,385	12,307		Nov 05 09:47 AM
de Verneuil Vanina	EVP and General Counsel	Nov 03 '25	Sale	5.86	1,365	8,003	80,595	Nov 04 07:40 PM
SATO VICKI L	Director	Nov 03 '25	Sale	5.64	22,000	124,047	1,210,391	Nov 04 11:58 AM
de Verneuil Vanina	Officer	Nov 03 '25	Proposed Sale	5.86	1,365	8,003		Nov 03 03:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 28 '25	Sale	6.50	24,453	159,006	14,574,083	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 29 '25	Sale	6.49	100	649	14,573,983	Oct 30 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 27 '25	Sale	6.05	66,403	401,585	14,598,536	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 24 '25	Sale	5.96	46,696	278,285	14,664,939	Oct 28 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 23 '25	Sale	5.99	154,383	924,723	14,711,635	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 22 '25	Sale	6.15	144,266	887,654	14,866,018	Oct 24 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 20 '25	Sale	6.20	220,535	1,367,273	15,119,959	Oct 22 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 21 '25	Sale	6.30	109,675	690,974	15,010,284	Oct 22 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 21 '25	Proposed Sale	6.27	834,202	5,230,447		Oct 21 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 15 '25	Sale	6.07	16,671	101,196	15,353,338	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 16 '25	Sale	6.10	12,844	78,366	15,340,494	Oct 17 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 09 '25	Sale	6.14	249,060	1,529,926	15,372,309	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 10 '25	Sale	6.08	2,300	13,973	15,370,009	Oct 14 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 08 '25	Sale	6.05	466,242	2,819,785	15,621,369	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 07 '25	Sale	5.60	72,133	404,154	16,087,611	Oct 09 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 03 '25	Sale	5.56	450,342	2,501,785	16,233,699	Oct 07 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Oct 06 '25	Sale	5.69	73,955	420,641	16,159,744	Oct 07 04:30 PM
SVF Endurance (Cayman) Limited	10% Owner	Oct 03 '25	Proposed Sale	5.71	1,668,404	9,526,587		Oct 03 05:00 PM
SATO VICKI L	Director	Oct 01 '25	Sale	5.84	22,000	128,396	1,232,391	Oct 02 11:53 AM
VICKI LEE SATO	Director	Oct 01 '25	Proposed Sale	5.71	66,000	376,860		Oct 01 04:32 PM
SATO VICKI L	Director	Sep 02 '25	Sale	4.99	22,000	109,811	1,254,391	Sep 03 01:50 PM
SATO VICKI L	Director	Aug 01 '25	Sale	4.99	22,000	109,699	1,276,391	Aug 04 12:27 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 15 '25	Sale	5.47	6,796	37,162	108,204	Jul 17 06:46 PM
Eisner Mark	EVP and Chief Medical Officer	Jul 17 '25	Sale	5.47	3,586	19,629	104,618	Jul 17 06:46 PM
MARK EISNER	Officer	Jul 17 '25	Proposed Sale	5.41	3,586	19,400		Jul 17 04:18 PM
Mark Eisner	Officer	Jul 15 '25	Proposed Sale	5.47	6,796	37,162		Jul 15 08:11 PM
SATO VICKI L	Director	Jul 01 '25	Sale	5.10	22,000	112,207	1,298,391	Jul 02 05:03 PM
VICKI LEE SATO	Director	Jul 01 '25	Proposed Sale	5.04	66,000	332,640		Jul 01 04:25 PM
GEORGE SCANGOS	Former Director	Jun 11 '25	Proposed Sale	5.41	19,957	108,037		Jun 11 05:59 PM
GEORGE SCANGOS	Former Director	Jun 10 '25	Proposed Sale	5.48	50,000	273,885		Jun 10 05:04 PM
GEORGE SCANGOS	Former Director	Jun 09 '25	Proposed Sale	5.41	50,000	270,590		Jun 09 05:55 PM
Napolitano Janet	Director	Jun 02 '25	Sale	5.05	3,200	16,149	16,416	Jun 02 07:26 PM
JANET ANN NAPOLITANO	Director	Jun 02 '25	Proposed Sale	4.94	3,200	15,808		Jun 02 04:29 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '25	Sale	5.95	79,712	474,239	769,505	Apr 04 04:23 PM
Marianne De Backer	Officer and Director	Apr 03 '25	Proposed Sale	5.95	79,712	474,239		Apr 03 07:50 PM
de Verneuil Vanina	EVP and General Counsel	Feb 26 '25	Sale	9.14	7,373	67,402	79,460	Feb 27 12:39 PM
VANINA DE VERNEUIL	Officer	Feb 26 '25	Proposed Sale	9.10	7,373	67,094		Feb 26 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience